Skip to main content

Table 3 SUCRA values for four outcomes

From: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

OS PFS SAEs RP
Treatment SUCRA Treatment SUCRA Treatment SUCRA Treatment SUCRA
SP 0.80 PP 0.89 UP 0.03 MVP 0.32
PP 0.70 PP-Cet 0.86 SP 0.11 PP 0.36
PP-Cet 0.68 EP 0.75 PP 0.33 PP-Cet 0.37
UP 0.68 UP 0.74 PP-Cet 0.38 NP 0.41
NP 0.65 DP 0.55 PC 0.41 UP 0.42
EP 0.60 SP 0.48 NP 0.50 DP 0.46
DP 0.60 NP 0.41 EP 0.50 EP 0.47
MVP 0.35 PC-Cet 0.36 GP 0.60 GP 0.47
PC 0.29 PC 0.35 PC-Cet 0.69 SP 0.50
IC 0.28 MVP 0.28 IC 0.7 IC 0.69
PC-Cet 0.22 IC 0.17 DP 0.75 PC 0.69
GP 0.15 GP 0.15 MVP 1.0 PC-Cet 0.83
  1. Abbreviations: OS overall survival, PFS progression-free survival, SAE serious adverse events, RP radiation pneumonitis, SUCRA surface under the cumulative ranking curve, EP etoposide-cisplatin, PC paclitaxel-cisplatin/carboplatin, UP uracil/tegafur(UFT)-cisplatin, NP vinorelbine-cisplatin, PP pemetrexed-cisplatin/carboplatin, SP S-1-cisplatin, DP docetaxel-cisplatin, GP gemcitabine-cisplatin, MVP mitomycin-vindesine-cisplatin, IC irinotecan-carboplatin, Cet cetuximab